Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 24, 2023

SELL
$191.51 - $216.16 $258,921 - $292,248
-1,352 Reduced 5.77%
22,063 $4.68 Million
Q2 2023

Jul 25, 2023

SELL
$187.64 - $206.25 $1.17 Million - $1.29 Million
-6,240 Reduced 21.04%
23,415 $4.51 Million
Q1 2023

Apr 14, 2023

BUY
$127.59 - $203.08 $20,031 - $31,883
157 Added 0.53%
29,655 $6 Million
Q4 2022

Feb 08, 2023

SELL
$117.37 - $139.17 $76,407 - $90,599
-651 Reduced 2.16%
29,498 $3.79 Million
Q3 2022

Oct 25, 2022

SELL
$135.27 - $180.11 $177,609 - $236,484
-1,313 Reduced 4.17%
30,149 $4.13 Million
Q2 2022

Aug 12, 2022

BUY
$108.81 - $179.33 $359,399 - $592,326
3,303 Added 11.73%
31,462 $5.57 Million
Q1 2022

May 11, 2022

SELL
$119.61 - $157.85 $27,271 - $35,989
-228 Reduced 0.8%
28,159 $4.06 Million
Q4 2021

Feb 08, 2022

BUY
$142.57 - $190.86 $68,433 - $91,612
480 Added 1.72%
28,387 $4.39 Million
Q3 2021

Nov 02, 2021

BUY
$142.45 - $169.82 $3,703 - $4,415
26 Added 0.09%
27,907 $4.74 Million
Q2 2021

Aug 11, 2021

BUY
$135.08 - $161.1 $418,342 - $498,926
3,097 Added 12.5%
27,881 $4.4 Million
Q1 2021

May 14, 2021

BUY
$137.51 - $190.8 $63,117 - $87,577
459 Added 1.89%
24,784 $3.44 Million
Q4 2020

Feb 12, 2021

BUY
$164.63 - $211.93 $4 Million - $5.16 Million
24,325 New
24,325 $4.26 Million

Others Institutions Holding SGEN

About Seagen Inc.


  • Ticker SGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,664,992
  • Description
  • Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...
More about SGEN
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.